Skip to main content
    S

    Surgery Partners Inc (SGRY)

    Official site

    HEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ

    $26.79
    -0.16 (-0.59%)

    Market Cap: $3.53B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Surgery Partners Inc (SGRY) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Surgery Partners (SGRY) trades at 95.7x trailing earnings and 1.0x sales. Its P/E of 95.7x is above its 5-year median of 34.1x. Its forward P/E is 666.7x. The median P/E across 10 similar companies is 23.2x.

    Current Multiples

    Its forward P/E is above its trailing P/E, which implies earnings per share about 85.6% lower over the next year. Its free cash flow yield is 5.9%.

    MultipleValue
    P/E (trailing)95.7x
    Forward P/E666.7x
    Price to sales1.0x
    Price to book2.1x
    EV/EBITDA11.4x
    Price to FCF17.0x
    EV/FCF30.3x
    PEG1.7
    FCF yield5.9%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 25.0% above 0.8x and its P/B is 16.7% above 1.8x.

    MultipleCurrent5-year median10-year median
    P/E95.7x34.1xN/A
    P/S1.0x1.0x0.8x
    P/B2.1x1.8x1.8x
    Medians of month-end values through Oct 2026: 56 to 60 months (5-year) and 119 to 120 months (10-year).

    Valuation History

    Over the 5 of the 10 year ends shown that have a P/E, its P/E ranged from 22.5x in 2024 to 214.3x in 2022.

    Year endPriceP/EP/SP/B
    2025$15.4533.6x0.6x1.1x
    2024$21.1722.5x0.9x1.5x
    2023$31.9932.3x1.5x2.0x
    2022$27.86214.3x1.0x1.4x
    2021$53.41N/A1.7x4.1x
    2020$29.01N/A0.8x2.6x
    2019$15.66N/A0.4x1.1x
    2018$9.79N/A0.3x1.2x
    2017$12.10N/A0.4x0.9x
    2016$15.8526.0x0.7x79.0x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About SGRY

    What is SGRY's forward P/E ratio?

    Surgery Partners has a forward P/E ratio of 666.7x.

    Is SGRY stock overvalued?

    GNG's valuation label for SGRY is Fairly valued. Its P/E of 95.7x compares with a median of 23.2x across 10 similar companies.

    What is SGRY's price to sales ratio?

    Surgery Partners has a price to sales ratio of 1.0x.

    What is Surgery Partners's average P/E ratio over 5 years?

    Surgery Partners's median P/E over the last 5 years is 34.1x, from 56 month-end values through Oct 2026.

    What is SGRY's PEG ratio?

    Surgery Partners has a PEG ratio of 1.7.